Forest/PAION Desmoteplase Scare Is Brief: Trial Resumes After Two-Day Hold
This article was originally published in Pharmaceutical Approvals Monthly
A pre-Halloween scare for PAION/Forest's vampire bat protein-based stroke therapy desmoteplase resolved quickly when a halt on patient recruitment in a Phase IIb/III trial was lifted within two days of the announcement of a possible safety signal
You may also be interested in...
Development of Forest/Paion's clot dissolving protein desmoteplase for the treatment of acute ischemic stroke could be in question after a Phase III study failed to show an efficacy benefit in patients treated with the drug versus placebo
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011